Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide identification of ZCCHC10 targets in acute myeloid leukemia cells

ABSTRACT: Genome-wide identification of ZCCHC10 targets in acute myeloid leukemia cells

PROVIDER: PRJNA667353 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide identification of ZCCHC10 targets in acute myeloid leukemia cells

Project description:To explore which pathways ZCCHC10 is involved in acute myeloid leukemia (AML), we constructed ML-2 cells stably expressing ZCCHC10 (ML2-Zh10) or empty vector (ML2-Vec). Then, RNA-seq was performed to compare the mRNA profilings of ML2-ZH10 and ML2-Vec cells.

2024-09-01 | GSE159016 | GEO

Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells

Project description:Acute myeloid leukemia (AML) is a hematologic malignancy for which several epigenetic regulators have been identified as therapeutic targets. Here we report the development of cereblon-dependent degraders of IKZF2 and casein kinase 1 alpha (CK1α) termed DEG-35 and DEG-77. We utilized a structure-guided approach to develop DEG-35 as a nanomolar degrader of IKZF2, a hematopoietic specific transcription factor that contributes to myeloid leukemogenesis. DEG-35 possesses additional substrate specificity for the therapeutically relevant target CK1α which was identified through unbiased proteomics and a PRISM screen assay. Degradation of IKZF2 and CK1α blocks cell growth and induces myeloid differentiation in AML cell lines through CK1α–p53- and IKZF2-dependent pathways. Target degradation by DEG-35 or the analog DEG-77 delays leukemia progression in murine and human AML mice models. Overall, we provide a strategy for multi-targeted degradation of IKZF2/CK1α to enhance efficacy against AML that may be expanded to additional targets and indications.

2023-03-08 | PXD039474 | Pride

Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia

Project description:Label-free quantitation dataset from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.

2022-03-09 | MSV000089029 | MassIVE

Drug-resistant acute myeloid leukemia

Project description:Drug-resistant acute myeloid leukemia

| PRJNA828404 | ENA

Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia

Project description:A deep-scale proteome and phosphoproteome database from 44 representative Acute Myeloid Leukemia (AML) patients from the LAML TCGA dataset, and 6 healthy bone marrow derived controls including 3 lineage-depleted and 3 CD34+ selected bone marrows.

2022-03-07 | MSV000089012 | MassIVE

Stabilizing the Proteomes of Acute Myeloid Leukemia Cells: Implications for Cancer Proteomics

Project description:Data dependent analysis of acute myeloid leukemia samples in the presence and absence of the serine protease inhibitor DFP

2023-07-26 | MSV000092526 | MassIVE

IKAROS and MENIN are Functionally Cooperative Therapeutic Targets in Acute Myeloid Leukemia

Project description:IKAROS and MENIN are Functionally Cooperative Therapeutic Targets in Acute Myeloid Leukemia

| PRJNA707477 | ENA

A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia

Project description:A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia

| PRJNA412307 | ENA

Epigenetic studies in Acute Myeloid Leukemia

Project description:Epigenetic studies in Acute Myeloid Leukemia